Rx Product News

Published Online: Friday, August 2, 2013



Qsymia
Marketed by:
Vivus, Inc
Indication: Qsymia (phentermine and topiramate extended-release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 or greater or a BMI of 27 or greater with a weight-related comorbidity. Vivus, Inc, has announced the availability of Qsymia capsules in approximately 8000 certified retail pharmacies nationwide.
Dosage Form: Capsules (phentermine/topiramate extended-release): 3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg, and 15 mg/92 mg
For More Information: www.qsymia.com






Brisdelle
Marketed by:
Noven Pharmaceuticals, Inc
Indication: The FDA has approved Brisdelle (paroxetine) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Prior to this approval, hormone therapy was the only FDA-approved treatment for VMS. The low dose of paroxetine in Brisdelle has not been studied in psychiatric conditions; therefore, Brisdelle is not approved for psychiatric use. The recommended dosage is 7.5 mg once daily at bedtime.
Dosage Form: Capsules: 7.5 mg
For More Information: www.brisdelle.com




Nesina
Marketed by:
Takeda Pharmaceutical Company Limited
Indication: Nesina (alogliptin) was approved by the FDA this year as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Nesina is not for treatment of type 1 diabetes or diabetic ketoacidosis. The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily.
Dosage Form: Tablets: 6.25, 12.5, and 25 mg
For More Information: www.takedadiabetesadvantage.com




Zubsolv
Marketed by:
Orexo US, Inc
Indication: The FDA has approved Zubsolv (buprenorphine and naloxone) sublingual tablets for the maintenance treatment of opioid dependence. The drug is indicated for use as part of a complete treatment plan that includes counseling and psychosocial support. The recommended daily dose for maintenance treatment is 11.4 mg buprenorphine and 2.8 mg naloxone. Patients should be advised not to cut, chew, or swallow the tablets.
Dosage Form: Sublingual tablets (buprenorphine/naloxone): 1.4 mg/0.36 mg and 5.7 mg/1.4 mg
For More Information: www.orexo.com/en/Products/Zubsolv_Treatment_of_opioid_dependence

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$